A Chinese drugmaker says its coronavirus vaccine was found to be 79.3 percent effective at preventing infection in the final round of testing, moving Beijing closer to possibly being able to fulfil its pledge to supply other developing countries.

China National Pharmaceutical Group, Sinopharm, has applied for approval of its vaccine following the third and final stage of testing, a unit of the company, Beijing Biological Products Institute Ltd., said on its website. It would be the second vaccine from a China National Pharmaceutical Group, following a separate candidate developed by the company’s Wuhan Institute of Biological Products Ltd.

The Sinopharm vaccine relies on two doses, the company said, resembling to Western-developed vaccines. The two-sentence announcement gave no information about side effects, conditions required to transport and use the vaccine or other details.

Western-developed vaccines must be kept frozen at temperatures as low as minus 70 degrees Celsius (minus 94 Fahrenheit). Chinese developers have said theirs can be stored at 2 to 8 C (36 to 46 F). Chinese developers are testing vaccines in more than 12 countries, including Russia, Egypt and Mexico. Few details have been released, leaving experts abroad wondering about effectiveness and side effects.

Joe Biden blames Trump admn for ‘snail-pitch' vaccine rollout, pledges faster pace

Eight German care workers hospitalized after overdose of Pfizer Covid vaccine

COVID-19 Vaccine Distribution To Start In January: CEO SSI